Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
China Resources Double-Crane Pharmaceutical Co's quarterly Other Current Payables
declined
from Sep. 2025 (¥2,226 Mil) to Dec. 2025 (¥1,871 Mil) and
declined
from Dec. 2025 (¥1,871 Mil) to Mar. 2026 (¥1,788 Mil).
China Resources Double-Crane Pharmaceutical Co's annual Other Current Payables
declined
from Dec. 2023 (¥3,312 Mil) to Dec. 2024 (¥2,760 Mil) and
declined
from Dec. 2024 (¥2,760 Mil) to Dec. 2025 (¥1,871 Mil).
China Resources Double-Crane Pharmaceutical Co Other Current Payables Related Terms
China Resources Double-Crane Pharmaceutical Co Other Current Payables Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
China Resources Double-Crane Pharmaceutical Co Other Current Payables Chart
China Resources Double-Crane Pharmaceutical Co Annual Data
China Resources Double-Crane Pharmaceutical Co Other Current Payables Calculation
Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.
What does a Other Current Payables of ¥1,788 Mil mean?
China Resources Double-Crane Pharmaceutical Co (SHSE:600062) has a Other Current Payables of ¥1,788 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors.
Is China Resources Double-Crane Pharmaceutical Co's Other Current Payables too high?
China Resources Double-Crane Pharmaceutical Co's current Other Current Payables is ¥1,788 Mil. Overall, China Resources Double-Crane Pharmaceutical Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does China Resources Double-Crane Pharmaceutical Co's Other Current Payables compare to ZTS and UTHR?
China Resources Double-Crane Pharmaceutical Co's Other Current Payables of ¥1,788 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Drug Manufacturers company?
A good Other Current Payables depends on the Drug Manufacturers industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on China Resources Double-Crane Pharmaceutical Co and its competitors. China Resources Double-Crane Pharmaceutical Co's current Other Current Payables is ¥1,788 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is China Resources Double-Crane Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co (SHSE:600062) is currently considered Fairly Valued. The stock's GF Value™ is ¥18.81, compared to a current price of ¥17.30 — trading 8% below its estimated fair value. The current Other Current Payables is ¥1,788 Mil. China Resources Double-Crane Pharmaceutical Co's overall GF Score™ is 89/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For China Resources Double-Crane Pharmaceutical Co (SHSE:600062), the current Other Current Payables is ¥1,788 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is China Resources Double-Crane Pharmaceutical Co (SHSE:600062) Overvalued in 2026?
Based on GuruFocus' analysis, China Resources Double-Crane Pharmaceutical Co stock appears to be undervalued.
The current stock price of ¥17.30 is trading 8% below its estimated GF Value™ of ¥18.81.
GuruFocus considers China Resources Double-Crane Pharmaceutical Co to be Fairly Valued.
Key valuation signals for SHSE:600062:
Other Current Payables: ¥1,788 Mil
GF Value™: ¥18.81 vs. price of ¥17.30 (8% below fair value)
No single metric tells the full story. See the SHSE:600062 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
China Resources Double-Crane Pharmaceutical Co Business Description
China Resources Double-Crane Pharmaceutical Co Ltd is a China-based pharmaceutical company. It is engaged in developing, manufacturing and marketing a variety of medical products. The company's products cover different fields such as infusion field, cardiovascular and cerebrovascular fields, pediatrics, endocrine field and other areas.
89GF Score
Get the complete analysis for SHSE:600062
Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600062 has been successfully added to your 
